Fill and Finish processing of Biotech products

09:20 - 09:50

  • Protein aggregation is a major risk for patients
  • The root cause of aggregation is still highly debated: shear or interfacial effects
  • Whatever the root cause, some precautions and de-risking actions have to be taken for the scale up of the Fill & Finish process. Practical examples will be provided.

Jean-René Authelin, Global director of Pharmaceutical Engineering , Sanofi